Abstracts Archive - Page 1668 of 2425 - ACR Meeting Abstracts

Abstract Number: 2940 • 2015 ACR/ARHP Annual Meeting
Risk Factors for Late-Onset Thrombosis in Systemic Lupus Erythematosus (SLE)
Khawla Al-Ghanim¹, Jiandong Su², Stacey E. Morrison³, Samar Alharbi⁴, Mohammed Attar⁵, Dafna Gladman², Murray Urowitz^6,7 and Jorge Sánchez-Guerrero⁸, ¹Rheumatology, TWH, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Div Rheumatology Rm MP-10-304, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: Thrombotic events (TE) cause great morbidity and mortality in SLE patients. Studies of TE in SLE focus on early-onset TE. While the incidence of…
Abstract Number: 2941 • 2015 ACR/ARHP Annual Meeting
Outcomes in Lupus Nephritis Patients Previously Randomized to Receive Either Low Dose Cyclophosphamide Versus Oral Mycophenolate Mofetil on Azathioprine Maintenance
Manish Rathi¹, Ajay Jaryal², Ajay Goyal², Aman Sharma³, Pramod Gupta⁴ and Krishan Gupta², ¹Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁴Biostatistics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Management of SLE and lupus nephritis is challenging as it is always a trade off between remission, prevention of relapse and long term adverse…
Abstract Number: 2942 • 2015 ACR/ARHP Annual Meeting
Longitudinal Analyses of Progression of Brain Athrophy in Childhood-Onset Systemic Lupus Erythematosus
Aline Tamires Lapa¹, Nailu A. Sinicato², Mariana Postal¹, Fernando Cendes³, Roberto Marini Sr.⁴ and Simone Appenzeller⁵, ¹Medicine, State University of Campinas, Campinas, Brazil, ²Pediatrics, State University of Campinas, Campinas, Brazil, ³State University of Campinas, Campinas, Brazil, ⁴Pediatric Rheumatology Unit, State University of Campinas, São Paulo, Brazil, ⁵Division of Rheumatology, Faculty of Medical Science, State University of Campinas, São Paulo, Brazil
Background/Purpose: The CNS involvement in cSLE has been described to occur from 25-90% in childhood-onset systemic lupus erythematosus (cSLE). The aim of the study was…
Abstract Number: 2943 • 2015 ACR/ARHP Annual Meeting
Preliminary Population-Based Incidence and Prevalence Estimates of Systemic Lupus Erythematous from the Manhattan Lupus Surveillance Program
Peter M. Izmirly¹, Isabella Wan², Sara Sahl¹, Jill P. Buyon³, H. Michael Belmont⁴, Jane E. Salmon^5,6, Joan M. Bathon⁷, Anca Askanase⁸, Laura Geraldino-Pardilla⁹, Yousaf Ali¹⁰, Ellen M. Ginzler¹¹, Chaim Putterman¹², Caroline Gordon¹³, Charles G. Helmick¹⁴ and Hilary Parton¹⁵, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Rheumatology, New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵Dept of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁸Columbia University College of Physicians & Surgeons, New York, NY, ⁹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ¹⁰Icahn School of Medicine at Mount Sinai, New York, NY, ¹¹Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ¹³School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁴Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ¹⁵Bureau of Epidemiology Services, New York City Department of Health and Mental Hygiene, Long Island City, NY
Background/Purpose: Given widely varying estimates of the incidence and prevalence of Systemic Lupus Erythematous (SLE) in the US and the absence of data for certain…
Abstract Number: 2944 • 2015 ACR/ARHP Annual Meeting
Presepsin (sCD14 subtype) Concentration Is Elevated and Reflects Disease Activity in Systemic Lupus Erythematous Patients
Kohei Tsujimoto¹, Masaaki Fujita², Yutaka Shinkawa², Iku Shirasugi¹, Masashi Taniguchi¹, Saori Hatachi³ and Masato Yagita⁴, ¹Department of Clinical Immunology and Rheumatology, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ²Department of Clinical Immunology and Rheumatology C, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ³Department of Rheumatology, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ⁴Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan
Background/Purpose: Presepsin (sCD14 subtype) has recently been identified as a novel biomarker for predicting sepsis. Because presepsin is produced as a consequence of cellular phagocytosis,…
Abstract Number: 2945 • 2015 ACR/ARHP Annual Meeting
Diffuse Alveolar Hemorrhage in SLE: Risk Factors, Response to Therapy, and Survival
Nayef M. Kazzaz¹, Patrick S. Coit², Emily E. Lewis³, W Joseph McCune⁴, Amr H. Sawalha² and Jason S. Knight², ¹Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI, ⁴Int Med/ Rheum, University of Michigan, Ann Arbor, MI
Background/Purpose: While diffuse alveolar hemorrhage (DAH) is recognized as a life-threatening complication of SLE, little is known about its risk factors and response to therapy. …
Abstract Number: 2946 • 2015 ACR/ARHP Annual Meeting
Mortality Among SLE Patients in the National Data Bank for Rheumatic Diseases
Kaleb Michaud¹, Sofia Pedro² and Patricia P. Katz³, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: To investigate risk of mortality among SLE patients cohort in the NDB.Methods: Systemic lupus erythematous (SLE) and non-inflammatory rheumatic disease (NIRD) patients were studied…
Abstract Number: 2947 • 2015 ACR/ARHP Annual Meeting
Association of Anti-NR2 and U1RNP Antibodies with Neurotoxic Inflammatory Mediators in Cerebrospinal Fluid from Patients with Neuropsychiatric Systemic Lupus Erythematosus
Seiko Kondo-Ishikawa¹, Takao Fujii², Nozomi Ishigooka¹, Kosaku Murakami¹, Ran Nakashima¹, Yoshitaka Imura¹, Motomu Hashimoto², Naoichiro Yukawa¹, Hajime Yoshifuji¹, Koichiro Ohmura¹ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Autoantibodies (auto Abs) in cerebrospinal fluid (CSF) and inflammatory mediators (IMs) may be involved in the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE). Previous…
Abstract Number: 2948 • 2015 ACR/ARHP Annual Meeting
How Do Patients with Newly Diagnosed SLE Present? a Multicenter Cohort Analysis to Inform the Development of New Classification Criteria for SLE
Marta Mosca¹, Zahi Touma², Karen H. Costenbader³, Bimba F. Hoyer⁴, Chiara Tani¹, Alexander Fine⁵, Sara Tedeschi³, Jorge Medina-Rosas⁶, Valentina Lorenzoni⁷, Gian Domenico Sebastiani⁸, Thomas Dorner⁹ and on behalf of the SLE Classification Criteria Steering committee, ¹University of Pisa, Pisa, Italy, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Charité University Medicine, Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶University of Toronto, Toronto, ON, Canada, ⁷SSSUP, Pisa, Italy, ⁸Osp. San Camillo, Roma, Italy, ⁹Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine, Berlin, Germany
Background/Purpose: SLE onset may be insidious with clinically evident disease developing over years. Current SLE classification criteria may not classify patients with early SLE well.…
Abstract Number: 2949 • 2015 ACR/ARHP Annual Meeting
Differential Serum Cytokine Profile in Patients with Systemic Lupus Erythematosus and Posterior Reversible Encephalopathy Syndrome: A Single-Center Study
Jorge Alcocer-Varela¹, Diana Gómez-Martín¹, Javier Merayo-Chalico² and Ana Barrera-Vargas¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are susceptible to the development of posterior reversible encephalopathy syndrome (PRES). The main theory about the physiopathology of…
Abstract Number: 2950 • 2015 ACR/ARHP Annual Meeting
Using Electronic Health Record Algorithms to Accurately Identify Patients with Systemic Lupus Erythematosus
April Barnado¹, Joshua C. Denny² and Leslie J. Crofford¹, ¹Medicine, Vanderbilt University, Nashville, TN, ²Biomedical Informatics, Medicine, Vanderbilt University, Nashville, TN
Background/Purpose: To harness the data in electronic health records (EHRs) and administrative databases to study systemic lupus erythematosus (SLE), it is important to identify patients…
Abstract Number: 2951 • 2015 ACR/ARHP Annual Meeting
Anti-NR2 Antibody and Blood-Brain Barrier Disruption in Systemic Lupus Erythematosus Patients with Cognitive Dysfunction
Gaurav Gulati¹, Philip Iffland², Damir Janigro², Bin Zhang³ and Michael Luggen⁴, ¹Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ³Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁴Division of Immunology, University of Cincinnati Medical Center, Cincinnati, OH
Background/Purpose: Cognitive Dysfunction (CD) is one of the most common manifestations of neuropsychiatric SLE (NPSLE) and one of the most devastating. The pathogenesis of CD…
Abstract Number: 2952 • 2015 ACR/ARHP Annual Meeting
Diagnosis of Primary Neuropsychiatric Systemic Lupus Erythematosus: Attribution Models Versus Physician Judgment
Antonis Fanouriakis^1,2, Cristina Pamfil³, Simona Rednic³, Prodromos Sidiropoulos¹, George Bertsias^4,5 and Dimitrios Boumpas^5,6,7, ¹Rheumatology, Clinical Immunology, and Allergy, University of Crete, Medical School, University Hospital, Heraklion, Greece, ²Foundation of Research and Technology, University of Molecular Biology and Biotechnology, Heraklion, Greece, ³Rheumatology, University of Medicine and Pharmacy, Cluj-Napoca, Romania, ⁴Rheumatology, Clinical Immunology, and Allergy, University of Crete, Heraklion, Greece, ⁵Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Heraklion, Crete, Greece, ⁶Biomedical Research Foundation, Academy of Athens, Athens, Greece, ⁷Clinical Immunology and Rheumatology, National And Kapodistrian University of Athens, Medical School, Athens, Greece
Background/Purpose: Attribution of neuropsychiatric manifestations to systemic lupus erythematosus per se (“primary NPSLE”) is challenging and depends largely on physician judgment based on clinical and…
Abstract Number: 2953 • 2015 ACR/ARHP Annual Meeting
The Emergency Room and SLE: What Characteristics Are Associated with Increased Emergency Room Utilization in Lupus Patients?
Kimberly Trotter¹, Kichul Ko¹, Gabrielle Liu¹ and Tammy Utset², ¹Medicine, University of Chicago, Chicago, IL, ²University of Chicago, Chicago, IL
Background/Purpose: There is sparse data examining the characteristics of SLE patients who frequent the emergency room (ER). Data suggest that lupus patients with certain sociodemographic…
Abstract Number: 2954 • 2015 ACR/ARHP Annual Meeting
Serum and CSF Biomarkers of Neuropsychiatric Involvement in Primary Sjogren Syndrome and Systemic Lupus Erythematosus
Maria Boge Lauvsnes¹, Anne Bolette Tjensvoll², Ingeborg Kvivik³, Roald Omdal⁴ and Chaim Putterman⁵, ¹Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway, ²Department of Neurology, Stavanger University Hospital, Stavanger, Norway, ³Reasearch Department, Stavanger University Hospital, Stavanger, Norway, ⁴Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁵Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric manifestations are commonly observed in both SLE and primary Sjšgren's syndrome (pSS). However, making an accurate diagnosis can be challenging. Multiple serum and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].